HCPCS
J9177
1 unit = 0.25 mg
Phase 1
Identify what you're billing
The 0.25 mg unit basis is the single biggest source of Padcev billing errors.
The 0.25 mg unit basis — read this first CMS HCPCS verified May 2026
J9177 has an unusual quarter-milligram unit basis. Get this wrong and every claim is short.
HCPCS J9177 — "Inj enfort vedo-ejfv 0.25mg" — defines one billable unit as
0.25 mg of enfortumab vedotin-ejfv. This is different from the typical monoclonal-antibody
J-code convention where 1 unit = 1 mg (e.g., J9299 nivolumab, J9271 pembrolizumab). The mismatch creates a
consistent billing trap: practices used to billing 1 mg per unit will undercut every Padcev claim by a
factor of 4.
The arithmetic. Multiply administered milligrams by 4 to get J9177 units.
- Max dose 125 mg → 500 units (not 125)
- 100 mg dose (80 kg patient) → 400 units (not 100)
- 75 mg dose (60 kg patient) → 300 units (not 75)
- 50 mg dose (40 kg patient) → 200 units (not 50)
Why the quarter-milligram basis? Antibody-drug conjugates with potent cytotoxic payloads (Padcev's payload is monomethyl auristatin E / MMAE) are often coded at sub-milligram precision so CMS can match payment to small dose adjustments without large step changes in payment. The Trodelvy code (J9317, sacituzumab govitecan-hziy) uses a 2.5 mg unit basis — a different but similarly non-standard convention. Always verify the unit basis on every ADC J-code; do not assume 1 mg = 1 unit.
Dosing & unit math FDA label verified May 2026
From the FDA prescribing information (BLA 761137).
Adult monotherapy (post-platinum + post-PD-1/L1)
- 1.25 mg/kg IV over 30 minutes on Days 1, 8, and 15 of every 28-day cycle
- Maximum dose: 125 mg regardless of body weight (cap applies above ~100 kg)
- 3 doses per cycle = 13 cycles per year typical = 39 infusions per year max
- 1 unit = 0.25 mg → multiply administered mg by 4
Cisplatin-ineligible monotherapy (post-PD-1/L1)
- Same 1.25 mg/kg (max 125 mg) IV Days 1, 8, 15 of 28-day cycle
- Indication for patients ineligible for cisplatin who progressed on a prior PD-1/L1 inhibitor
- Largely superseded by 1L Keytruda combo for treatment-naive cisplatin-ineligible patients
Padcev + Keytruda combo (EV-302) — 1L advanced urothelial
- Padcev 1.25 mg/kg (max 125 mg) IV on Days 1 and 8 of every 21-day cycle
- Keytruda 200 mg IV q3w on Day 1 (or 400 mg IV q6w extended interval)
- Cycle length changes from 28 to 21 days — Day 15 dose is dropped
- Both drugs administered on Day 1 (Padcev first, then Keytruda); Padcev only on Day 8
- Continue until disease progression or unacceptable toxicity
Worked example — 80 kg patient, 1L Keytruda combo
# Patient weight: 80 kg · Padcev dose: 1.25 mg/kg = 100 mg
Drug units billed per Padcev dose: 400 (J9177 = 100 mg × 4)
Vials used: 4 (3 × 30 mg + 1 × 20 mg = 110 mg) — 10 mg waste
HCPCS: J9177 · Modifier: JZ on 400 administered units + JW on 40 wasted units
Admin: 96413 (30-min chemo IV) + 96417 (additional drug, Keytruda)
# 21-day cycle, 2 Padcev doses per cycle
Total Padcev units per cycle: 800 (Days 1 + 8)
Padcev cost per cycle (Q2 2026 ASP+6%): ~$29,365.60
+ Keytruda 200 mg per cycle: see /drugs/keytruda
# Annualized (~17 cycles per year)
Padcev units billed: 13,600
Padcev drug cost: ~$499,215 before sequestration
Drug units billed per Padcev dose: 400 (J9177 = 100 mg × 4)
Vials used: 4 (3 × 30 mg + 1 × 20 mg = 110 mg) — 10 mg waste
HCPCS: J9177 · Modifier: JZ on 400 administered units + JW on 40 wasted units
Admin: 96413 (30-min chemo IV) + 96417 (additional drug, Keytruda)
# 21-day cycle, 2 Padcev doses per cycle
Total Padcev units per cycle: 800 (Days 1 + 8)
Padcev cost per cycle (Q2 2026 ASP+6%): ~$29,365.60
+ Keytruda 200 mg per cycle: see /drugs/keytruda
# Annualized (~17 cycles per year)
Padcev units billed: 13,600
Padcev drug cost: ~$499,215 before sequestration
Dose modifications
- Skin reactions: Hold for grade 2 worsening or grade 3; permanent discontinuation for SJS/TEN or grade 4
- Hyperglycemia: Hold if blood glucose >250 mg/dL; resume when controlled
- Pneumonitis: Hold for grade 2; permanent discontinuation for grade 3+
- Peripheral neuropathy: Hold for grade 2/3; permanent discontinuation for grade 4 or recurrent grade 3
- Dose reductions: 1.0 mg/kg → 0.75 mg/kg → 0.5 mg/kg — recalculate units after each reduction
Keytruda combo billing (EV-302) FDA verified Dec 2023
Practice-changing 1L for advanced urothelial cancer in cisplatin-eligible AND cisplatin-ineligible patients.
EV-302 demonstrated significant overall survival benefit for Padcev + Keytruda vs platinum-based chemotherapy in 1L locally advanced or metastatic urothelial cancer. FDA granted accelerated approval in April 2023 and full approval in December 2023. The combo is now NCCN preferred 1L regardless of cisplatin eligibility.
| Padcev mono | Padcev + Keytruda combo | |
|---|---|---|
| Indication | Post-platinum + post-PD-1/L1; or cisplatin-ineligible post-PD-1/L1 | 1L advanced urothelial (cisplatin-eligible OR ineligible) |
| Cycle length | 28 days | 21 days |
| Padcev dose | 1.25 mg/kg (max 125 mg) | 1.25 mg/kg (max 125 mg) |
| Padcev infusion days | Days 1, 8, 15 (3 per cycle) | Days 1, 8 (2 per cycle) |
| Keytruda dose | N/A | 200 mg q3w (Day 1) or 400 mg q6w |
| Padcev HCPCS | J9177 (0.25 mg/unit) | J9177 (0.25 mg/unit) |
| Keytruda HCPCS | N/A | J9271 (1 mg/unit) — see Keytruda page |
| Admin CPT (Day 1) | 96413 + 1-hr observation | 96413 + 96417 (additional drug) |
| Admin CPT (Day 8) | 96413 | 96413 |
| Concurrent PA | Padcev only | BOTH drugs — submit Padcev + Keytruda PAs together |
Cycle-length error trap. The most common error after the unit-basis mistake is using the
28-day cycle for combo patients. Combo is a 21-day cycle with only Days 1 and 8 — no
Day 15 dose. Billing a Day 15 Padcev infusion on a combo regimen will trigger payer scrutiny and may be
denied as not medically necessary per the EV-302 protocol.
Sequencing on Day 1. Per the EV-302 protocol, Padcev is administered first, then Keytruda.
Bill the Padcev administration as the initial drug (96413) and the Keytruda administration as additional
sequential drug (96417). Both drugs use 30-min infusions; total combined chair time ~90 minutes including
gap. Keytruda also requires its own NDC and unit calculation — see Keytruda
(J9271) for that side of the combo.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
51144-020-01 / 51144-0020-01 |
20 mg single-dose lyophilized vial — 1 vial per carton | Smaller-weight patients; combinations with 30 mg vial to reach target mg |
51144-030-01 / 51144-0030-01 |
30 mg single-dose lyophilized vial — 1 vial per carton | Standard sizing; most adult doses use 3-4 of these vials |
Vial selection for common doses
| Patient kg | Dose (mg) | Vials | Total mg drawn | Waste (mg) | Units billed |
|---|---|---|---|---|---|
| 40 kg | 50 mg | 2 × 30 mg | 60 mg | 10 mg | 200 admin + 40 JW |
| 60 kg | 75 mg | 2 × 30 mg + 1 × 20 mg | 80 mg | 5 mg | 300 admin + 20 JW |
| 80 kg | 100 mg | 3 × 30 mg + 1 × 20 mg | 110 mg | 10 mg | 400 admin + 40 JW |
| 100 kg+ (capped) | 125 mg max | 4 × 30 mg + 1 × 20 mg (or 3 × 30 + 2 × 20) | 140 mg / 130 mg | 15 mg / 5 mg | 500 admin + 60 / 20 JW |
Use the NDC matching the actual vial(s) used. Document each vial NDC on the claim if both
20 mg and 30 mg vials are used in the same dose. Some payers require vial-level NDC granularity for ADCs.
Phase 2
Code the claim
Chemo admin codes apply (ADC with cytotoxic MMAE payload). JW is common, not exception.
Administration codes CPT verified May 2026
Padcev is an antibody-drug conjugate with cytotoxic MMAE payload — chemo admin codes apply.
| Code | Description | When to use |
|---|---|---|
96413 |
Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Primary code for Padcev. 30-min standard infusion fits within the 1-hour window. |
96415 |
Chemotherapy administration, IV infusion; each additional hour | Rarely needed for Padcev monotherapy. Pair with 96413 if combined chair time exceeds 1 hour. |
96417 |
Chemotherapy administration; each additional sequential infusion (different substance/drug), up to 1 hour | Use on Day 1 of combo for Keytruda following Padcev. |
96365 / 96366 |
Therapeutic IV infusion (non-chemo) | NOT appropriate. Padcev's MMAE payload is cytotoxic; chemo admin codes are correct. |
Why chemo admin for an antibody-drug conjugate: Padcev's antibody (anti-Nectin-4) is the
delivery vehicle; the active cytotoxic agent is monomethyl auristatin E (MMAE), released intracellularly
after Nectin-4 binding and internalization. CPT chemotherapy administration codes apply to ADCs with
cytotoxic payloads regardless of mechanism. Do not bill 96365 (therapeutic infusion) — it pays
materially less and miscategorizes the drug.
Modifiers CMS verified May 2026
JZ + JW — both common on Padcev
Effective July 1, 2023, CMS requires either JZ (no waste) or JW (waste reported) on every single-dose container claim. Padcev's 20 mg and 30 mg vial sizes paired with weight-based dosing mean partial-vial waste is the norm, not the exception. JW is common; pure JZ-only claims occur only when administered mg lands exactly on a vial-size sum.
Standard pattern: split JZ admin line + JW waste line
For a 100 mg dose using 4 vials totaling 110 mg: bill the administered 100 mg (400 units) on the primary drug line (with JZ), then add a separate claim line for the discarded 10 mg (40 units) with the JW modifier. Both lines reference J9177; CMS pays for both administered and discarded portions of the single-dose vial.
Common error: Forgetting the JW waste line. CMS audits flag patterns where every Padcev
claim is JZ-only — statistically improbable given the vial sizes and weight-based dosing. Wasted drug
is reimbursable but must be reported with documented vial counts.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (skin assessment for SJS/TEN risk often qualifies during cycle 1).
340B modifiers (JG, TB)
For 340B-acquired Padcev, follow your MAC's current 340B modifier policy. Astellas's billing guide does not provide 340B-specific instructions.
ICD-10-CM — urothelial cancer FY2026 verified May 2026
All FDA-approved Padcev indications are urothelial carcinoma. Use the most specific C67.x code for the bladder anatomic site, plus secondary codes for metastatic sites if applicable.
| ICD-10 | Description | Notes |
|---|---|---|
C67.0 | Malignant neoplasm of trigone of bladder | Specify if known |
C67.1 | Malignant neoplasm of dome of bladder | Specify if known |
C67.2 | Malignant neoplasm of lateral wall of bladder | Specify if known |
C67.3 | Malignant neoplasm of anterior wall of bladder | Specify if known |
C67.4 | Malignant neoplasm of posterior wall of bladder | Specify if known |
C67.5 | Malignant neoplasm of bladder neck | Specify if known |
C67.6 | Malignant neoplasm of ureteric orifice | Specify if known |
C67.7 | Malignant neoplasm of urachus | Specify if known |
C67.8 | Malignant neoplasm of overlapping sites of bladder | Specify if known |
C67.9 | Malignant neoplasm of bladder, unspecified | Use only when site not documented |
C65.x | Malignant neoplasm of renal pelvis | Upper tract urothelial covered by FDA label |
C66.x | Malignant neoplasm of ureter | Upper tract urothelial covered by FDA label |
C68.x | Malignant neoplasm of other/unspecified urinary organs | Less common urothelial sites (e.g., urethra C68.0) |
C77–C79 | Secondary malignancies (LN, distant) | Add as secondary codes for metastatic disease |
No biomarker testing required. Unlike Opdivo, Keytruda, and many other oncology drugs,
Padcev does not require companion diagnostic testing for prior auth. Nectin-4 expression is
near-universal in urothelial cancer; FDA did not require a companion diagnostic at approval. Document
urothelial histology (transitional cell / urothelial carcinoma) and prior therapy line.
Site of care & place of service Verified May 2026
UnitedHealthcare and Aetna run aggressive site-of-care UM for high-cost specialty oncology drugs including Padcev. Expect HOPD steerage after the first 3 months of therapy unless the patient has active toxicity management requiring hospital-level monitoring (especially during cycle 1 SJS/TEN surveillance window).
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician oncology office | 11 | CMS-1500 / 837P | Preferred by commercial UM |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM |
| Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored after first 3 months |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after first 3 months |
| Patient home | 12 | CMS-1500 (with home infusion) | Generally not used — SJS/TEN monitoring requires clinical setting |
Cycle 1 hospital-based admin defensible: Most SJS/TEN cases occur during cycle 1. A
medical-necessity letter requesting cycle-1 HOPD administration with dermatology backup is generally
accepted. Plan transition to office or AIC starting cycle 2.
Claim form field mapping Astellas billing guide 2026
From the Astellas Pharma Support Solutions HCP coding & coverage materials.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + 51144-020-01 (20 mg) or 51144-030-01 (30 mg) + UN1 (each) |
| HCPCS J9177 + JZ (administered) | 24D (drug line) | Units = mg administered × 4 |
| HCPCS J9177 + JW (discarded) | 24D (waste line) | Separate line; units = mg discarded × 4 |
| Drug units | 24G | Quarter-mg units; do not enter mg |
| CPT 96413 (admin line) | 24D (admin line) | 30-min infusion fits within 1-hour window |
| CPT 96417 (combo Day 1 only) | 24D (admin line) | For Keytruda following Padcev on combo Day 1 |
| ICD-10 | 21 | C67.x bladder, C65.x renal pelvis, C66.x ureter |
| PA number | 23 | Required by all major payers; combo requires concurrent Keytruda PA |
Phase 3
Get paid
PA is universal; combo requires concurrent Keytruda PA. Site-of-care UM is active.
Payer policy snapshot Reviewed May 2026
Universal PA. Concurrent Keytruda PA when combined. No biomarker requirement.
| Payer | PA? | Combo PA | Site-of-care UM |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes | Concurrent Padcev + Keytruda PAs required for EV-302 regimen | Aggressive: HOPD steerage via Optum-managed program after 3 months |
| Aetna Medical Drug + CPB |
Yes | Concurrent PA required; combo regimen documented in PA narrative | Yes (separate Site-of-Care policy; oncology drugs steered out of HOPD after 3 months) |
| BCBS plans Vary by plan |
Yes | Generally aligned with NCCN bladder cancer guidelines + FDA label | Plan-specific; most have specialty-oncology site-of-care steering |
| Cigna / Evernorth Specialty oncology policy |
Yes | Concurrent Keytruda PA; FDA label adherence enforced | Yes for high-cost oncology drugs |
| Medicare (MAC LCDs) Evolving |
No (Part B) | FDA-approved indication adherence; verify current MAC LCD | N/A (FFS) |
Step therapy
Generally NOT required for the FDA-labeled 1L Keytruda combo (it is itself the preferred regimen). Monotherapy indications by definition include a step (post-platinum and/or post-PD-1/L1). Document prior therapy lines clearly in the PA narrative: drug name, dates of treatment, response, progression date.
NCCN guidelines
NCCN Bladder Cancer Guidelines list Padcev + Keytruda as preferred 1L regimen (category 1) for both cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. Padcev monotherapy is preferred 2L+ post-platinum and post-PD-1/L1. Verify current NCCN version with the PA submission for category support.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9177
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$36.707
per 0.25 mg unit
125 mg max dose
$18,353.50
500 units × ASP+6%
100 mg dose (80 kg)
$14,682.80
400 units × ASP+6%
Per-mg equivalent: $36.707 ÷ 0.25 mg = ~$146.83 per mg. For
comparison with mg-based J-codes: Padcev is among the most expensive oncology drugs by per-mg cost,
reflecting both the antibody complexity and the ADC manufacturing process.
Annualized cost (monotherapy, 28-day cycle, 80 kg patient): 100 mg × 3 doses/cycle
× 13 cycles/year = ~$572,629/year (Medicare ASP+6%, before sequestration). Combo
regimen (21-day cycle, 2 doses/cycle, ~17 cycles/year) for 80 kg patient: Padcev portion ~$499,215/year.
After ~2% sequestration: subtract approximately 1.7%.
Coverage
No NCD specific to enfortumab vedotin. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J9177 for FDA-approved on-label indications with appropriate ICD-10 documentation. LCD language for the EV-302 combo regimen continues to evolve; verify current MAC LCD before billing combo cycles.
Code history
- J9177 — permanent code, "Inj enfort vedo-ejfv 0.25mg" (initial FDA accelerated approval December 2019; pre-permanent-code period used unclassified J3490 / J9999)
Patient assistance — Astellas + Pfizer programs Verified May 2026
- Astellas Pharma Support Solutions: 1-800-477-6472 — benefits investigation, prior authorization assistance, appeal support, copay program enrollment
- Padcev Co-pay Program: commercial copay support; eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
- Pfizer Oncology Together: 1-877-744-5675 — co-development partner support; benefits investigation, financial assistance referrals
- Astellas Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements
- Foundations: for Medicare patients, refer to PAN, HealthWell, CancerCare bladder/urothelial funds — verify open funds quarterly (urothelial-specific funds tend to open and close quickly)
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max for a Padcev + Keytruda combo regimen? Run a CareCost Estimate
— J9177 pre-loaded.
Phase 4
Fix problems
Unit-basis errors, missing JW, and SJS/TEN safety documentation are the top three.
Safety & monitoring FDA label verified May 2026
BOXED WARNING — SJS/TEN. Stevens-Johnson syndrome and toxic epidermal necrolysis,
sometimes fatal, have occurred in patients treated with Padcev. Most cases occurred during cycle 1.
Permanently discontinue Padcev for confirmed SJS/TEN or for grade 4 / recurrent grade 3
skin reactions. Hold for grade 2 worsening or grade 3 skin reactions and consider dermatology consultation.
Other significant warnings & precautions
- Hyperglycemia: Risk increased in patients with pre-existing diabetes or BMI ≥30. Monitor blood glucose; hold for blood glucose >250 mg/dL until controlled.
- Pneumonitis / interstitial lung disease: Monitor for new or worsening cough, dyspnea, hypoxia. Hold for grade 2; permanent discontinuation for grade 3+.
- Peripheral neuropathy: Most common adverse event. Monitor at every visit; dose modify or discontinue based on grade.
- Ocular disorders: Dry eye is most common. Counsel patients on artificial tears prophylaxis; refer to ophthalmology for symptoms.
- Infusion reactions: Monitor during and after infusion. Slow or interrupt infusion for grade 1/2; permanent discontinuation for grade 3/4.
- Embryo-fetal toxicity: Effective contraception during treatment + 2 months after last dose (females) or 4 months (males with female partners of reproductive potential).
Monitoring documentation that supports billing & PA
- Skin assessment (full-body) at every infusion, especially during cycle 1 — supports same-day E/M with modifier 25
- Baseline + ongoing fasting blood glucose / HbA1c, particularly in diabetic patients
- Pulmonary symptom screening at every visit
- Neuropathy grading (CTCAE) at every visit
- Ophthalmology referral on symptom onset
- Pregnancy testing prior to first dose in females of reproductive potential
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Underbilled units (4x off) | Billed mg instead of 0.25-mg units | Resubmit with corrected units = mg × 4. The 125 mg max dose = 500 units, not 125. |
| Missing JW for waste | Partial-vial waste not reported | Add JW line for discarded units. Document vial count + total mg drawn vs administered. |
| JZ missing on adult claim | Single-dose vial claim without JZ | Add JZ to administered-units line. Required since 7/1/2023 on every claim with no waste. |
| Wrong admin code (96365) | Therapeutic IV billed instead of chemo IV | Resubmit with 96413. Padcev is an ADC with cytotoxic MMAE payload — chemo admin codes apply. |
| Combo PA mismatch | Padcev approved but Keytruda not, or vice versa | Submit concurrent PAs for both drugs referencing EV-302 1L urothelial regimen. Resolve before infusion. |
| Day 15 dose on combo cycle | 28-day cycle billed instead of 21-day combo cycle | Combo is Days 1 + 8 only (21-day cycle). Drop the Day 15 charge or convert to 28-day mono cycle. |
| Wrong NDC format | Non-NDC qualifier or 10-digit format expected as 11-digit | Use N4 qualifier + 11-digit NDC: 51144-0020-01 (20 mg) or 51144-0030-01 (30 mg). |
| Site of care (HOPD) | HOPD administration after first 3 months on commercial plan with site-of-care UM | Move to office (POS 11) or AIC (POS 49). Submit medical necessity letter if cycle 1 SJS/TEN monitoring required. |
| Indication / line of therapy not documented | ICD-10 alone insufficient; prior therapy line not documented | Submit complete clinical history: prior platinum, prior PD-1/L1, response, progression dates. |
| Dose exceeds 125 mg cap | Calculated 1.25 mg/kg dose for >100 kg patient billed at full weight-based mg | Cap at 125 mg / 500 units regardless of body weight per FDA label. |
Frequently asked questions
What is the HCPCS code for Padcev?
Padcev (enfortumab vedotin-ejfv) is billed under HCPCS J9177 — "Inj enfort vedo-ejfv
0.25mg." One unit equals 0.25 mg, NOT 1 mg. This is the most common biller error on J9177:
mistakenly billing 1 unit per mg understates the claim by 4x. The standard 125 mg max dose is billed as
500 units (125 ÷ 0.25). A 100 mg dose is billed as 400 units.
How many units of J9177 do I bill for a Padcev dose?
Multiply the mg administered by 4 to get units. The maximum 125 mg dose = 500 units. An 80 kg patient at 1.25 mg/kg = 100 mg = 400 units. A 60 kg patient at 1.25 mg/kg = 75 mg = 300 units. Always cap at 125 mg / 500 units regardless of body weight per FDA label. Document body weight and dose calculation in the chart.
What administration CPT do I use for Padcev?
CPT 96413 — "Chemotherapy administration, IV infusion technique; up to 1 hour, single
or initial substance/drug." Padcev is an antibody-drug conjugate with cytotoxic monomethyl auristatin E
(MMAE) payload, so chemo admin codes apply. Standard infusion is 30 minutes, fitting within the 1-hour
window. Add 96417 for the additional sequential drug (Keytruda) on combo Day 1. Do NOT bill
96365 (therapeutic infusion) — it pays less and miscategorizes the drug.
Do I bill JZ or JW for Padcev?
Both are common. Padcev comes in 20 mg and 30 mg single-dose vials, so most patient-specific doses produce
partial-vial waste. Bill JW with the discarded units on a separate claim line and the
administered units on a primary line (effectively JZ-style). Example: 75 mg dose uses 2 × 30 mg + 1 × 20 mg
= 80 mg drawn, 5 mg discarded = 20 units JW. One of JZ or JW must appear on every J9177 claim per CMS's
July 2023 single-dose container policy.
What is the Medicare reimbursement for J9177?
For Q2 2026, the Medicare Part B payment limit for J9177 is $36.707 per 0.25 mg unit (ASP + 6%) — equivalent to ~$146.83 per mg. The 125 mg max dose reimburses at approximately $18,353.50 (500 units × ASP+6%). A typical 100 mg dose reimburses at ~$14,682.80 (400 units). Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.
How is Padcev dosed with Keytruda for 1L urothelial cancer?
The EV-302 regimen (FDA full approval December 2023): Padcev 1.25 mg/kg (max 125 mg) IV on Days 1 and 8 of
a 21-day cycle PLUS Keytruda (pembrolizumab) 200 mg IV q3w on Day 1 (or 400 mg IV q6w).
Note the cycle length changes from 28 days (mono) to 21 days (combo) and the Day 15 dose is dropped. Both
drugs require concurrent prior authorization. Bill J9177 + J9271 (Keytruda) on
the same DOS for Day 1; J9177 only on Day 8. CPT 96413 + 96417 (additional sequential drug) for Day 1
combo administration. See the Keytruda (J9271) page for that side of the
combo.
Does Padcev require prior authorization?
Yes — every major payer requires PA for Padcev. UHC, Aetna, BCBS, and Cigna all require: confirmed urothelial carcinoma diagnosis (ICD-10 C67.x or C65.x/C66.x for upper tract), documentation of prior therapy line (post-platinum + post-PD-1/L1 for monotherapy; treatment-naive for the Keytruda combo), and concurrent Keytruda PA when used in combination. No biomarker testing is required — Nectin-4 expression is near-universal in urothelial cancer and FDA did not require a companion diagnostic. Site-of-care steerage is common after the first 3 months.
What is the SJS/TEN warning on Padcev?
Padcev carries an FDA boxed warning for serious skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be fatal. Most cases occur during cycle 1. Permanently discontinue Padcev if SJS or TEN is confirmed or for grade 4 / recurrent grade 3 skin reactions. Closely monitor for skin reactions starting cycle 1 and consider dermatology consult for severe presentations. Document skin assessment at every infusion for medical-necessity audit defense.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Padcev HCP — Astellas Pharma Support Solutions
- DailyMed — PADCEV (enfortumab vedotin-ejfv) Prescribing Information
- FDA Padcev label PDF (current revision)
- FDA — Padcev + Keytruda full approval announcement (Dec 2023)
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS J9177 reference
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna Clinical Policy Bulletins — oncology drug policies
- NCCN Bladder Cancer Guidelines
- FDA National Drug Code Directory
- Pfizer Oncology Together — co-development partner support
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS, Cigna) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, indications, SJS/TEN warning text | Event-driven | Tied to manufacturer document version + FDA label revision date. |
| NCCN preferred regimen status | Event-driven | Reviewed on each NCCN Bladder Cancer Guideline version release. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
manufacturer, payer, and NCCN documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify
each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: Astellas Padcev HCP materials 2026. FDA label: most recent 2024 revision (BLA 761137). Coverage of Padcev monotherapy (post-platinum + post-PD-1/L1; cisplatin-ineligible post-PD-1/L1) and Padcev + Keytruda 1L combo (EV-302, full approval Dec 2023). SJS/TEN boxed warning prominently flagged.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list and dosing are verified against the current FDA label revision and NCCN Bladder Cancer Guidelines. We do not paraphrase from billing-software vendor blogs.